What is Laboratory Corporation of America Holdings?
It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services.
LH · Verdict
Moderate reward · moderate risk
LH's standout is cash flow; growth and profitability weigh on the picture.
Based on 88% data coverage
LH · Verdict
9% free-cash-flow margin
Rev +5.6% CAGR · earnings -11.8%
6% net margin · 11% ROE
Model-based scoring. For information only — not financial advice.
It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C, prostate-specific antigens, sexually transmitted diseases, hepatitis C, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company is listed on the NYSE in USA, operating in the Healthcare sector, with a market capitalisation of 23.44B, and a P/E ratio of 27.0x.
The scoring profile indicates limited reward potential at this time, with momentum and size offering the most support. Risk indicators are moderate, consistent with typical market exposure.
For informational purposes only. Not financial advice.